After plugging billions into its manufacturing network to meet rampant demand for Mounjaro and Zepbound, Eli Lilly is looking ...

In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Many compounding pharmacies make unbranded versions of semaglutide ... "If compounded semaglutide goes away as well, then I ...

Attorney General Kwame Raoul is warning Illinois residents seeking GLP-1 medications – Ozempic, Wegovy, Mounjaro, Zepbound ...

The Food and Drug Administration announced that branded tirzepatide, the active ingredient in Eli Lilly's weight loss drug Zepbound, is no longer in short supply. That decision will largely ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.

CEDAR RAPIDS, Iowa — As 2024 comes to a close, proposed limits on weight loss drugs could pose a challenge for one of the year’s biggest health trends. Amanda Bonello – who lives in Iowa ...

The USA compounding pharmacies market is on track for significant growth, estimated to reach USD 5,156.2 million in 2024, ...